Literature DB >> 25708908

Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers.

Brian A Gordon1, Jeffrey M Zacks2, Tyler Blazey3, Tammie L S Benzinger4, John C Morris5, Anne M Fagan6, David M Holtzman7, David A Balota8.   

Abstract

There is a growing emphasis on examining preclinical levels of Alzheimer's disease (AD)-related pathology in the absence of cognitive impairment. Previous work examining biomarkers has focused almost exclusively on memory, although there is mounting evidence that attention also declines early in disease progression. In the current experiment, 2 attentional control tasks were used to examine alterations in task-evoked functional magnetic resonance imaging data related to biomarkers of AD pathology. Seventy-one cognitively normal individuals (females = 44, mean age = 63.5 years) performed 2 attention-demanding cognitive tasks in a design that modeled both trial- and task-level functional magnetic resonance imaging changes. Biomarkers included amyloid β42, tau, and phosphorylated tau measured from cerebrospinal fluid and positron emission tomography measures of amyloid deposition. Both tasks elicited widespread patterns of activation and deactivation associated with large task-level manipulations of attention. Importantly, results from both tasks indicated that higher levels of tau and phosphorylated tau pathologies were associated with block-level overactivations of attentional control areas. This suggests early alteration in attentional control with rising levels of AD pathology.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer; Alzheimer's disease; Amyloid; Attention; Biomarkers; Dementia; fMRI; ptau; tau

Mesh:

Substances:

Year:  2015        PMID: 25708908      PMCID: PMC4417039          DOI: 10.1016/j.neurobiolaging.2015.01.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  56 in total

1.  Neuroimaging studies of shifting attention: a meta-analysis.

Authors:  Tor D Wager; John Jonides; Susan Reading
Journal:  Neuroimage       Date:  2004-08       Impact factor: 6.556

2.  Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming.

Authors:  David A Balota; Chi-Shing Tse; Keith A Hutchison; Daniel H Spieler; Janet M Duchek; John C Morris
Journal:  Psychol Aging       Date:  2010-03

3.  Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response.

Authors:  S Duke Han; Wes S Houston; Amy J Jak; Lisa T Eyler; Bonnie J Nagel; Adam S Fleisher; Gregory G Brown; Jody Corey-Bloom; David P Salmon; Leon J Thal; Mark W Bondi
Journal:  Neurobiol Aging       Date:  2006-01-24       Impact factor: 4.673

4.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

5.  Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.

Authors:  Andrew J Aschenbrenner; David A Balota; Chi-Shing Tse; Anne M Fagan; David M Holtzman; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2014-09-15       Impact factor: 3.295

6.  The utility of Stroop task switching as a marker for early-stage Alzheimer's disease.

Authors:  Keith A Hutchison; David A Balota; Janet M Duchek; Janet M Ducheck
Journal:  Psychol Aging       Date:  2010-09

7.  Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults.

Authors:  Janet M Duchek; David A Balota; Jewell B Thomas; Abraham Z Snyder; Patrick Rich; Tammie L Benzinger; Anne M Fagan; David M Holtzman; John C Morris; Beau M Ances
Journal:  Neuropsychology       Date:  2013-09       Impact factor: 3.295

Review 8.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

Review 9.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

10.  Quantitative analysis of PiB-PET with FreeSurfer ROIs.

Authors:  Yi Su; Gina M D'Angelo; Andrei G Vlassenko; Gongfu Zhou; Abraham Z Snyder; Daniel S Marcus; Tyler M Blazey; Jon J Christensen; Shivangi Vora; John C Morris; Mark A Mintun; Tammie L S Benzinger
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  15 in total

1.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

2.  Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults.

Authors:  Brian T Gold; Christopher A Brown; Jonathan G Hakun; Leslie M Shaw; John Q Trojanowski; Charles D Smith
Journal:  Neurobiol Aging       Date:  2017-06-24       Impact factor: 4.673

3.  Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability.

Authors:  Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; John C Morris; David A Balota
Journal:  J Cogn Neurosci       Date:  2020-11-02       Impact factor: 3.225

4.  Alzheimer's pathology targets distinct memory networks in the ageing brain.

Authors:  Anne Maass; David Berron; Theresa M Harrison; Jenna N Adams; Renaud La Joie; Suzanne Baker; Taylor Mellinger; Rachel K Bell; Kaitlin Swinnerton; Ben Inglis; Gil D Rabinovici; Emrah Düzel; William J Jagust
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

5.  Functional neural correlates of facial affect recognition impairment following TBI.

Authors:  Arianna Rigon; Michelle W Voss; Lyn S Turkstra; Bilge Mutlu; Melissa C Duff
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

6.  Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficits.

Authors:  Peter R Millar; David A Balota; Geoffrey B Maddox; Janet M Duchek; Andrew J Aschenbrenner; Anne M Fagan; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2017-02-16       Impact factor: 3.295

7.  A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimer's disease: The adult children study.

Authors:  Andrew J Aschenbrenner; David A Balota; Brian A Gordon; Roger Ratcliff; John C Morris
Journal:  Neuropsychology       Date:  2016-02       Impact factor: 3.295

8.  Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.

Authors:  Nicole S McKay; Aylin Dincer; Vidushri Mehrotra; Andrew J Aschenbrenner; David Balota; Russ C Hornbeck; Jason Hassenstab; John C Morris; Tammie L S Benzinger; Brian A Gordon
Journal:  Neurobiol Aging       Date:  2022-01-10       Impact factor: 5.133

9.  Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease.

Authors:  Andrew J Aschenbrenner; Brian A Gordon; Anne M Fagan; Suzanne E Schindler; David A Balota; John C Morris; Jason J Hassenstab
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  β-Amyloid Deposition Is Associated with Decreased Right Prefrontal Activation during Task Switching among Cognitively Normal Elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Yaakov Stern
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.